Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06673914

EFFECTS OF OLEUROPEIN ON BLOOD PARAMETERS AND INFLAMMATORY MARKERS IN ADULTS WITH METABOLIC SYNDROME

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Atlas University · Academic / Other
Sex
All
Age
18 Years – 49 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to determine the effect of 6 weeks supplementation of oleuropein on individuals diagnosed with metabolic syndrome. The baseline and end biochemical parameters and anthropometric measurements will be compared with control subjects.

Detailed description

This study was conducted to investigate the effect of adding oleuropein to the medical nutrition therapy of individuals with metabolic syndrome on their anthropometric measurements and biochemical parameters. Sub-objectives of the study; Determining the presence of inflammation in patiens with metabolic syndrome Determination of the effect of diet and diet combined with oleuropein on both fasting blood glucose, insulin and blood lipid profile. Determination of both anti-inflammatory and antidiabetic effects of oleuropein. Determination of the effect of diet and diet combined with oleuropein on anthropometric measurements. The aim of this study is to compare the anthropometric measurements and biomarkers of patients with metabolic syndrome as a result of the medical nutrition therpy with consumption of olive leaf extract (2 times a day) that has been contain 100 mg oleuropein for 6 weeks.

Conditions

Interventions

TypeNameDescription
BEHAVIORALControl Group: Diet GroupPatient in "Diet Group" and "Oleuropein and Diet Group" will be given a personalized diet and be followed up by a dietician.
DIETARY_SUPPLEMENTOleuropein and Diet GroupDietary Supplement: Oleuropein (Olive Leaf Extract) Patients in "Oleuropein and Diet Group" will receive 200 mg/day oleuropein supplement and personalized diet followed up by a dietician.

Timeline

Start date
2024-11-01
Primary completion
2024-12-30
Completion
2025-01-15
First posted
2024-11-05
Last updated
2024-11-05

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06673914. Inclusion in this directory is not an endorsement.